OPHTHALMOLOGY, vol.120, no.1, pp.130-139, 2013 (SCI-Expanded)
Objective: To evaluate long-term safety of intravitreal ranibizumab 0.5-mg injections in neovascular age-related macular degeneration (nAMD).